Cited by 491Genetics and Neurodevelopmental DisordersRNA and protein synthesis mechanismsNeuroscience and Neuropharmacology Research

The translation of translational control by FMRP: therapeutic targets for FXS

Open access
Darnell, Jennifer C, Klann, Eric·2013·Nature Neuroscience

Abstract

De novo protein synthesis is necessary for long-lasting modifications in synaptic strength and dendritic spine dynamics that underlie cognition. Fragile X syndrome (FXS), characterized by intellectual disability and autistic behaviors, holds promise for revealing the molecular basis for these long-term changes in neuronal function. Loss of function of the fragile X mental retardation protein (FMRP) results in defects in synaptic plasticity and cognition in many models of the disease. FMRP is a polyribosome-associated RNA-binding protein that regulates the synthesis of a set of plasticity-reated proteins by stalling ribosomal translocation on target mRNAs. The recent identification of mRNA targets of FMRP and its upstream regulators, and the use of small molecules to stall ribosomes in the absence of FMRP, have the potential to be translated into new therapeutic avenues for the treatment of FXS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nn.3379

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Darnell, J. C., & Klann, E.
Affiliations
  • Rockefeller University (US)
  • New York University (US)
Corresponding author
  • Darnell, Jennifer C
  • Klann, Eric
Venue
Nature Neuroscience
Published
2013-04-14
Volume
16
Issue
11
Pages
1530-1536
ISSN
  • 1097-6256 (ISSN-L)
  • 1546-1726
OpenAlex
W2001215117
Cited by
491
References
98
Citations by year
2026: 21 · 2025: 21 · 2024: 33 · 2023: 26 · 2022: 44 · 2021: 35 · 2020: 37 · 2019: 41 · 2018: 46 · 2017: 41 · 2016: 41 · 2015: 53 · 2014: 37 · 2013: 13
FWCI
5.89
Type
journal article
Language
en
Open access
Locations
  • Nature Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Defense
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke (NS-047384, R01NS047384)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD040647, R01HD040647)
  • Congressionally Directed Medical Research Programs
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
FMRP, fragile X syndrome, translational regulation, mRNA-binding proteins, ribosome stalling, synaptic plasticity, dendritic spines, cognitive impairment, autism spectrum disorder, therapeutic target, small molecules, RNA-binding proteins
MeSH terms
Animals, Fragile X Syndrome, Humans, Intellectual Disability, Neuronal Plasticity, RNA, Messenger, Protein Biosynthesis, Receptors, Metabotropic Glutamate, Fragile X Mental Retardation Protein, Fragile X Messenger Ribonucleoprotein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review